2026 Xiamen Cross-Border E-Commerce Fair: A Professional View of Peptide Sourcing

LUMIRABIO at the sixth Xiamen cross-border fair

The exhibition took place from June 8 to 10, 2026, at the Xiamen International Conference and Exhibition Center.

It brought together cross-border platforms, supply-chain companies, logistics providers and export-oriented brands across consumer, health, nutrition, beauty and other sectors.

This was LUMIRABIO's first appearance at the event.

Our team met cross-border sellers, overseas buyers, platform representatives and supply-chain participants.

Discussions covered peptide raw materials, research workflows, intermediates, quality requirements, documentation and potential project cooperation.

The exhibition widened the audience for peptide sourcing.

It also showed why pharmaceutical and research materials require a more structured conversation than ordinary consumer inventory.

Why a cross-sector exhibition matters to peptide companies

Pharmaceutical companies usually qualify suppliers through specialized industry channels, technical reviews and quality audits.

Discovery increasingly also happens across broader digital-commerce and international supply-chain networks.

Participating in Xiamen helped us understand the questions that arise when a buyer first encounters peptide materials outside a conventional pharmaceutical exhibition.

Interest in GLP-1-related development, research peptides, beauty peptides and other peptide-based health concepts has increased category visibility.

LUMIRABIO sees a strategic window for international business development as professional buyers search for stable, quality-controlled and document-supported sources.

Channel reach alone does not define product category.

An API, research material, intermediate, cosmetic ingredient and finished medicinal product still follow different use, documentation and market pathways.

Peptide programs and technical categories discussed

At the exhibition, our team presented and discussed semaglutide, tirzepatide and retatrutide programs.

Semaglutide and tirzepatide are active ingredients in approved prescription finished products in defined jurisdictions and indications.

Retatrutide remains investigational, and no drug containing it had been approved by the U.S.

FDA as of this update.

LUMIRABIO's technical platform covers R&D, synthesis, purification, lyophilization and quality testing.

For priority peptide programs, we manage mature synthesis processes, impurity control, batch-to-batch consistency, stable production and supply planning against project-defined requirements.

Specifications, documents, production and supply entity, use and target-market eligibility are confirmed in the project file.

Other discussions covered Selank, Semax, copper tripeptide and acetyl hexapeptide-related projects across research, cosmetic-ingredient and other professional contexts.

Their legal category and permitted use vary by jurisdiction; they are presented here as project topics, not as consumer products or approved treatments.

Why peptide raw materials are drawing cross-border attention

Peptide medicines and candidates are used or studied across metabolic disease, oncology, immune modulation, infectious disease, rare disease and other areas.

The commercial success of approved GLP-1 medicines, continued multi-agonist research and growth of peptide-enabled discovery have increased upstream interest in sequences, modifications, impurity control and scalable supply.

China's integrated synthesis, purification, lyophilization, testing and supply-chain ecosystem gives qualified suppliers a responsive base for international projects.

LUMIRABIO combines these functions in a peptide-focused platform and uses project qualification to align the requested product, evidence package and destination requirements.

We view cross-border channels as a way to discover and support qualified business customers, including pharmaceutical companies, research organizations, intermediaries and technical buyers, not as a shortcut around product or market requirements.

Cross-border access and destination-market qualification

For the United States, FDA states that imported human drugs and their components, including APIs, must meet applicable requirements concerning registration, listing, drug applications, labeling and current good manufacturing practice.

FDA has also warned about direct-to-consumer marketing of unapproved GLP-1 products and specifically notes restrictions affecting retatrutide.

Other destinations apply their own rules.

Product classification, importing route, intended application, customs description, responsible legal entities and documentation should be established before shipment.

ICH Q7 provides an internationally recognized GMP framework for APIs intended for use in human medicinal products, while the exact application depends on the material, stage, site and market.

What qualified buyers should define before an RFQ

A useful cross-border peptide inquiry begins with a technical and regulatory brief, not only a product name.

That brief allows the LUMIRABIO team to align route, specification, testing, documentation, packaging, logistics and commercial scope.

• Molecule, sequence, salt or counter-ion and required material form
• Intended use and development stage
• Target jurisdiction and responsible importing entity
• Required purity, impurity limits and analytical methods
• Quantity, packaging, storage and destination
• Quality, traceability and regulatory documents
• Patent, freedom-to-operate and sales-permission constraints

From an exhibition conversation to a qualified project

The Xiamen exhibition gave LUMIRABIO a useful view of how platforms, buyers and service providers approach international sourcing.

It also reinforced a practical distinction: channel reach initiates a conversation, while technical, quality, legal and regulatory qualification turns it into a viable project.

We thank the organizer, visitors and our team for three days of discussion.

Buyers with a defined molecule, use, specification and target market can now continue the conversation through a project-specific review.